97048-13-0 Usage
Description
Urofollitropin, also known as follicle-stimulating hormone (FSH), is a hormone that plays a crucial role in the development of ovarian follicles and the regulation of the menstrual cycle. It is a glycoprotein hormone that stimulates the growth and maturation of ovarian follicles, leading to the production of mature eggs for ovulation. Urofollitropin is available in various brand names, such as Bravelle (Ferring Pharmaceuticals), Fertinex (Serono), and Metrodin (Serono). It is typically presented as an almost white or slightly yellowish powder.
Uses
Used in Reproductive Medicine:
Urofollitropin is used as a fertility treatment for women with ovulatory disorders or those undergoing assisted reproductive technologies, such as in vitro fertilization (IVF). It is administered to stimulate the growth and maturation of ovarian follicles, leading to the production of multiple mature eggs for fertilization.
Used in Hormone Replacement Therapy:
Urofollitropin can also be used as a hormone replacement therapy for women experiencing menopause or those with hypogonadism, helping to alleviate symptoms associated with hormonal imbalances.
Used in Research and Development:
In addition to its clinical applications, Urofollitropin is used in research settings to study the mechanisms of follicular development, ovulation, and fertility. It can also be utilized in the development of new treatments and therapies for reproductive disorders and fertility issues.
Clinical Use
Urofollitropin, a natural product like the menotropins, is obtained from the urine of
postmenopausal women and then highly purified so as to contain only FSH, reportedly with only
minute amounts of LH. Urofollitropin is used for its ability to stimulate follicle development, such
as in women undergoing drug-induced pituitary suppression (GnRH antagonist or superagonist)
for purposes of IVF (i.e., multiple follicle development or egg donation). When the number and
size of the ovarian follicles are correct, as determined by ultrasound, hCG is administered so as
to effect ovulation, and the oocytes are retrieved for IVF.
This drug also is indicated for women who have infertility caused by polycystic ovary syndrome,
which generally is observed clinically as enlarged, cystic ovaries containing relatively small
follicles. These patients often develop hirsutism, their androgen and LH levels appear elevated
while their FSH levels are low, and the early exposure to these improper hormone levels may be
causing the follicular atresia. The patient's monthly cycle is controlled by previous pituitary
suppression via treatment with a GnRH superagonist or antagonist; urofollitropin, as an
exogenous source of FSH, is administered and stimulates follicle maturation to preovulatory
size, with little or no exposure of the follicles to additional LH. When the follicles have matured
to preovulatory size, ovulation is assisted by the administration of hCG. The couple is then
advised to engage in sexual intercourse daily, beginning on the day before hCG administration
and until ovulation has occurred.
Check Digit Verification of cas no
The CAS Registry Mumber 97048-13-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,0,4 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 97048-13:
(7*9)+(6*7)+(5*0)+(4*4)+(3*8)+(2*1)+(1*3)=150
150 % 10 = 0
So 97048-13-0 is a valid CAS Registry Number.
InChI:InChI=1/C42H65N11O12S2/c1-6-21(4)33-40(63)52-34(22(5)54)41(64)49-28(16-31(44)56)37(60)50-29(19-67-66-18-25(43)35(58)47-27(38(61)51-33)15-23-9-11-24(55)12-10-23)42(65)53-13-7-8-30(53)39(62)48-26(14-20(2)3)36(59)46-17-32(45)57/h9-12,20-22,25-30,33-34,54-55H,6-8,13-19,43H2,1-5H3,(H2,44,56)(H2,45,57)(H,46,59)(H,47,58)(H,48,62)(H,49,64)(H,50,60)(H,51,61)(H,52,63)
